Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
BAX vs ICU
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
BAX vs ICU — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $9.04B | $29M |
| Revenue (TTM) | $11.32B | $881K |
| Net Income (TTM) | $-1.10B | $-14M |
| Gross Margin | 30.1% | 95.3% |
| Operating Margin | -2.7% | -15.8% |
| Forward P/E | 9.2x | — |
| Total Debt | $10.00B | $574K |
| Cash & Equiv. | $1.97B | $2M |
BAX vs ICU — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| Baxter Internationa… (BAX) | 100 | 32.5 | -67.5% |
| SeaStar Medical Hol… (ICU) | 100 | 1.9 | -98.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BAX vs ICU
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BAX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -42.4% 10Y total return vs ICU's -98.1%
- -9.7% margin vs ICU's -15.5%
- 3.9% yield; the other pay no meaningful dividend
ICU is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.06
- Rev growth 12.0%, EPS growth 78.1%
- Lower volatility, beta 1.06, current ratio 0.55x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.0% revenue growth vs BAX's 5.7% | |
| Quality / Margins | -9.7% margin vs ICU's -15.5% | |
| Stability / Safety | Beta 1.06 vs BAX's 1.37 | |
| Dividends | 3.9% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +291.9% vs BAX's -41.8% | |
| Efficiency (ROA) | -5.4% ROA vs ICU's -88.0% |
BAX vs ICU — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BAX vs ICU — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — BAX and ICU each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BAX is the larger business by revenue, generating $11.3B annually — 12849.0x ICU's $881,000. BAX is the more profitable business, keeping -9.7% of every revenue dollar as net income compared to ICU's -15.5%. On growth, ICU holds the edge at +169.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $11.3B | $881,000 |
| EBITDAEarnings before interest/tax | $671M | -$14M |
| Net IncomeAfter-tax profit | -$1.1B | -$14M |
| Free Cash FlowCash after capex | $501M | -$14M |
| Gross MarginGross profit ÷ Revenue | +30.1% | +95.3% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -15.8% |
| Net MarginNet income ÷ Revenue | -9.7% | -15.5% |
| FCF MarginFCF ÷ Revenue | +4.4% | -16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.9% | +169.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -112.0% | +88.2% |
Valuation Metrics
BAX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $9.0B | $29M |
| Enterprise ValueMkt cap + debt − cash | $17.1B | $28M |
| Trailing P/EPrice ÷ TTM EPS | -10.01x | -0.73x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.17x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 25.37x | — |
| Price / SalesMarket cap ÷ Revenue | 0.80x | 215.18x |
| Price / BookPrice ÷ Book value/share | 1.47x | — |
| Price / FCFMarket cap ÷ FCF | 27.99x | — |
Profitability & Efficiency
Evenly matched — BAX and ICU each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
BAX delivers a -16.5% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-119 for ICU. On the Piotroski fundamental quality scale (0–9), ICU scores 6/9 vs BAX's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -16.5% | -119.2% |
| ROA (TTM)Return on assets | -5.4% | -88.0% |
| ROICReturn on invested capital | -1.4% | — |
| ROCEReturn on capital employed | -1.7% | — |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.64x | — |
| Net DebtTotal debt minus cash | $8.0B | -$1M |
| Cash & Equiv.Liquid assets | $2.0B | $2M |
| Total DebtShort + long-term debt | $10.0B | $574,000 |
| Interest CoverageEBIT ÷ Interest expense | -0.83x | -209.88x |
Total Returns (Dividends Reinvested)
BAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BAX five years ago would be worth $2,566 today (with dividends reinvested), compared to $189 for ICU. Over the past 12 months, ICU leads with a +291.9% total return vs BAX's -41.8%. The 3-year compound annual growth rate (CAGR) favors BAX at -24.1% vs ICU's -53.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -10.2% | +84.7% |
| 1-Year ReturnPast 12 months | -41.8% | +291.9% |
| 3-Year ReturnCumulative with dividends | -56.3% | -90.1% |
| 5-Year ReturnCumulative with dividends | -74.3% | -98.1% |
| 10-Year ReturnCumulative with dividends | -42.4% | -98.1% |
| CAGR (3Y)Annualised 3-year return | -24.1% | -53.7% |
Risk & Volatility
ICU leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ICU is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than BAX's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICU currently trades 95.6% from its 52-week high vs BAX's 53.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 1.06x |
| 52-Week HighHighest price in past year | $32.68 | $5.08 |
| 52-Week LowLowest price in past year | $15.73 | $0.22 |
| % of 52W HighCurrent price vs 52-week peak | +53.6% | +95.6% |
| RSI (14)Momentum oscillator 0–100 | 44.0 | 65.7 |
| Avg Volume (50D)Average daily shares traded | 8.7M | 150K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BAX is the only dividend payer here at 3.87% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — |
| Price TargetConsensus 12-month target | $19.75 | — |
| # AnalystsCovering analysts | 36 | — |
| Dividend YieldAnnual dividend ÷ price | +3.9% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.68 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
BAX leads in 2 of 6 categories (Valuation Metrics, Total Returns). ICU leads in 1 (Risk & Volatility). 2 tied.
BAX vs ICU: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BAX or ICU a better buy right now?
Analysts rate Baxter International Inc.
(BAX) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BAX or ICU?
Over the past 5 years, Baxter International Inc.
(BAX) delivered a total return of -74. 3%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: BAX returned -42. 4% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BAX or ICU?
By beta (market sensitivity over 5 years), SeaStar Medical Holding Corporation (ICU) is the lower-risk stock at 1.
06β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 29% more volatile than ICU relative to the S&P 500.
04Which is growing faster — BAX or ICU?
On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78.
1% year-over-year, compared to -37. 8% for Baxter International Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BAX or ICU?
Baxter International Inc.
(BAX) is the more profitable company, earning -8. 5% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps -8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BAX leads at -2. 7% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BAX or ICU?
In this comparison, BAX (3.
9% yield) pays a dividend. ICU does not pay a meaningful dividend and should not be held primarily for income.
07Is BAX or ICU better for a retirement portfolio?
For long-horizon retirement investors, Baxter International Inc.
(BAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 9% yield). Both have compounded well over 10 years (BAX: -42. 4%, ICU: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BAX and ICU?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BAX is a small-cap income-oriented stock; ICU is a small-cap quality compounder stock. BAX pays a dividend while ICU does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.